Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Oxygenta Pharmaceutical's 3-Year RORE % for the quarter that ended in Jun. 2026 was 50.00%.
The industry rank for Oxygenta Pharmaceutical's 3-Year RORE % or its related term are showing as below:
BOM:524636's 3-Year RORE % is ranked better than 83.16% of 944
companies
in the Drug Manufacturers industry
Industry Median: 2.245
vs BOM:524636: 50.00
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Oxygenta Pharmaceutical 3-Year RORE % Related Terms
Oxygenta Pharmaceutical 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Oxygenta Pharmaceutical's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxygenta Pharmaceutical 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Oxygenta Pharmaceutical's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Oxygenta Pharmaceutical's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.
Oxygenta Pharmaceutical (BOM:524636) has a 3-Year RORE % of 50.00 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Oxygenta Pharmaceutical and its competitors. According to the industry distribution chart, Oxygenta Pharmaceutical ranks #159 out of 944 companies in the Drug Manufacturers industry, placing it in the top 16.8%.
Is Oxygenta Pharmaceutical's 3-Year RORE % too high?
Oxygenta Pharmaceutical's current 3-Year RORE % is 50.00. The Drug Manufacturers industry median 3-Year RORE % is 2.25. Oxygenta Pharmaceutical's value of 50.00 is 2127.2% above this industry median. Based on the distribution chart, Oxygenta Pharmaceutical ranks #159 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Oxygenta Pharmaceutical has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Oxygenta Pharmaceutical's 3-Year RORE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Oxygenta Pharmaceutical ranks #159 out of 944 companies for 3-Year RORE %. This places Oxygenta Pharmaceutical in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 2.25. Oxygenta Pharmaceutical's value of 50.00 is 2127.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 2.25, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxygenta Pharmaceutical's current 3-Year RORE % of 50.00 is 2127.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Oxygenta Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxygenta Pharmaceutical's current 3-Year RORE % is 50.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxygenta Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Oxygenta Pharmaceutical (BOM:524636) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹84.80, compared to a current price of ₹63.85 — trading 24.7% below its estimated fair value. The current 3-Year RORE % is 50.00 and 2127.2% above the Drug Manufacturers industry median of 2.25. Oxygenta Pharmaceutical's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Oxygenta Pharmaceutical (BOM:524636), the current 3-Year RORE % is 50.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxygenta Pharmaceutical (BOM:524636) Overvalued in 2026?
Based on GuruFocus' analysis, Oxygenta Pharmaceutical stock appears to be undervalued.
The current stock price of ₹63.85 is trading 24.7% below its estimated GF Value™ of ₹84.80.
GuruFocus considers Oxygenta Pharmaceutical to be Modestly Undervalued.
Key valuation signals for BOM:524636:
3-Year RORE %: 50.00
GF Value™: ₹84.80 vs. price of ₹63.85 (24.7% below fair value)
Industry Position: 2127.2% above the Drug Manufacturers median (#159 of 944)
No single metric tells the full story. See the BOM:524636 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxygenta Pharmaceutical Ltd is a pharmaceutical company. It is engaged in the business activity of is engaged in manufacturing and selling of Pharmaceutical, medical, and veterinary preparations. The Company has one reportable segment, which is Pharmaceutical. The group carries out its business operations within India.
44GF Score
Get the complete analysis for BOM:524636
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524636 has been successfully added to your 
